Anti-IAPP antibody produced in rabbit

Islet amyloid polypeptide (IAPP, amylin), is a 37-residue peptide hormone co-secreted with insulin from the pancreatic β-cells. IAPP is processed from an 89-amino acid precursor pro-islet amyloid polypeptide (proIAPP) in pancreatic β-cells that undergoes complex posttranslational modifications including protease cleavage, C-terminal amidation and formation of an intramolecular disulfide bridge to produce the mature IAPP.

synthetic peptide corresponding to a sequence at the C-terminus of rat pro-IAPP, conjugated to KLH. The corresponding sequence is identical in mouse IAPP and has 74% sequence identity with human IAPP.

Anti-IAPP antibody produced in rabbit has been used in immunohistochemistry and immunofluorescence.

IAPP/Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing post-prandial spikes in blood glucose levels. IAPP has been linked to type 2 diabetes (T2DM) and the loss of islet b-cells. The human IAPP (20-29) region that has been found to be essential to amyloid formation is thought to be a key factor in the initiation of amyloid aggregation. Islet amyloid formation, initiated by the aggregation of IAPP, may contribute to this progressive loss of islet β-cells. Amyloid deposits deriving from IAPP are commonly found in pancreatic islets of patients suffering of T2DM, or containing an insulinoma cancer. IAPP, like β-amyloid peptide associated with Alzheimer′s disease, can induce apoptosis in insulin producing β-cells.

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.